Interim Phase IIb data from the SURVIVE trial support continued evaluation of SurVaxM, a survivin-targeting vaccine, in newly diagnosed glioblastoma and other tumor types.
Roswell Park Comprehensive Cancer Center has shared positive updates from its clinical development program evaluating SurVaxM, a vaccine targeting the protein survivin, for the treatment of patients with newly diagnosed glioblastoma. Following encouraging data from an interim analysis of the Phase IIb SURVIVE trial (NCT05163080), Roswell Park will continue moving forward with the study.1
While detailed results are unavailable as per regulatory requirements barring the disclosure of detailed findings from randomized, controlled studies still in progress, data from the interim analysis met prespecified standards for the research to continue.
In a press release, Ajay Abad, MD, a medical oncologist and brain cancer expert leading the study at Roswell Park—one of 11 US SURVIVE trial, said: “SurVaxM continues to show promise as a treatment option for patients with glioblastoma when paired with standard-of-care chemotherapy and radiation. SurVaxM’s excellent safety profile and tolerability to date also help optimize quality of life for patients with this highly aggressive cancer, where additional treatment options are direly needed.”
Roswell Park also shared updates on three other studies involving SurVaxM:
In the press release, Michael Ciesielski, PhD, assistant professor of neurosurgery at Roswell Park and CEO of MimiVax Inc., which is sponsoring the SURVIVE trial, added: “We are encouraged by the progress of our clinical trial and remain focused on our goal to develop innovative therapies that can drive meaningful improvements for patients with glioblastoma and other cancers. We are excited about the continued advancement of this important program.”
The SURVIVE trial was started based on positive outcomes from an earlier Phase IIa single-arm clinical trial (NCT02455557) of SurVaxM plus adjuvant temozolomide. Results from the study, shared by Roswell Park in December 2022, demonstrated that 60 of 63 evaluable patients were progression-free six months from diagnosis. Further, median progression-free survival was 11.4 months, and median overall survival was 25.9 months.3
In this Phase IIa study:
In a press release from the time, Ciesielski said: “We are finally starting to see immunotherapy having an impact upon difficult-to-manage diseases like glioblastoma and are excited to be able to contribute in a meaningful way to cancer care to provide hope for glioblastoma patients.”
1. Roswell Park Announces Positive Progress in Clinical Trial of Novel Immunotherapy SurVaxM. News release. Roswell Park Comprehensive Cancer Center. May 8, 2025. Accessed July 16, 2025. https://www.roswellpark.org/newsroom/202505-roswell-park-announces-positive-progress-clinical-trial-novel-immunotherapy-survaxm
2. SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE) (SURVIVE). ClinicalTrials.gov. Updated February 26, 2024. Accessed July 16, 2025. https://www.clinicaltrials.gov/study/NCT05163080
3. Clinical Trial of Roswell Park’s SurVaxM Glioblastoma Vaccine Reveals Promising Results. News release. Roswell Park Comprehensive Cancer Center. December 16, 2022. Accessed July 16, 2025. https://www.roswellpark.org/newsroom/202212-clinical-trial-roswell-parks-survaxm-glioblastoma-vaccine-reveals-promising-results
Imugene’s Azer-Cel Shows Promise in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
July 16th 2025Results from a Phase Ib trial (NCT03666000) show that azer-cel demonstrated a 75% overall response rate and a 55% complete response in patients with relapsed/refractory diffuse large b-cell lymphoma.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
CAHtalyst Trial Shows Crenessity Sustains Efficacy in Classic Congenital Adrenal Hyperplasia
July 14th 2025Results from the Phase III CAHtalyst show that patients treated with Crenessity for classic congenital adrenal hyperplasia achieved and maintained lower, more physiologic glucocorticoid doses while keeping key adrenal biomarkers at or below baseline levels.
